UBS published a research report stating that MEDBOT-B (02252) achieved a 77% year-over-year revenue increase in the first half of the year, surpassing the midpoint of the company's previous guidance. The net loss narrowed to 113 million RMB, outperforming profit forecasts, while gross margin declined by 6 percentage points to 41%. As of June 30, the company held cash reserves of 812 million RMB.

The report noted that although MEDBOT-B has not updated its full-year revenue guidance, UBS believes the company's overseas growth may continue to exceed domestic growth. The firm maintains a cautious stance regarding bidding and competition in China, sustaining its "neutral" rating while lowering the target price from HK$23.2 to HK$21.4.